State Of Wisconsin Investment Board Oric Pharmaceuticals, Inc. Transaction History

State Of Wisconsin Investment Board

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$6.63 - $12.93 $240,158 - $468,363	36,223 New	36,223 $256,000
Q2 2023 Aug 14, 2023	SELL	$4.95 - $8.4 $107,910 - $183,120	-21,800 Reduced 49.89%	21,900 $169,000
Q1 2023 May 15, 2023	SELL	$4.26 - $6.75 $439,632 - $696,600	-103,200 Reduced 70.25%	43,700 $249,000
Q4 2022 Feb 14, 2023	SELL	$2.41 - $5.89 $28,197 - $68,913	-11,700 Reduced 7.38%	146,900 $865,000
Q3 2022 Nov 14, 2022	SELL	$3.15 - $5.24 $99,540 - $165,584	-31,600 Reduced 16.61%	158,600 $508,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.07 $217,080 - $568,428	80,400 Added 73.22%	190,200 $852,000
Q1 2022 May 13, 2022	BUY	$4.54 - $16.1 $325,064 - $1.15 Million	71,600 Added 187.43%	109,800 $586,000
Q3 2021 Nov 12, 2021	BUY	$15.9 - $25.22 $31,720 - $50,313	1,995 Added 5.51%	38,200 $799,000
Q2 2021 Aug 12, 2021	BUY	$17.37 - $25.34 $413,492 - $603,218	23,805 Added 191.98%	36,205 $640,000
Q4 2020 Feb 03, 2021	SELL	$20.32 - $39.8 $30,480 - $59,699	-1,500 Reduced 10.79%	12,400 $420,000
Q2 2020 Aug 12, 2020	BUY	$25.68 - $38.12 $356,952 - $529,868	13,900 New	13,900 $469,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.